Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals. In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.
Pegloticase is a recombinant porcine-like uricase. Similarly to rasburicase, both enzymes metabolise uric acid to allantoin. This reduces the risk of precipitates, since allantoin is five to ten times more soluble than uric acid.
In contrast to rasburicase, pegloticase is pegylated to increase its elimination half life from about eight hours to ten or twelve days and to decrease the immunogenicity of the foreign uricase protein. This modification allows for an application just once every two to four weeks, making this drug suitable for long-term treatment.